Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07139990 | Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)(PRISM) | recruiting | Phase 1 | 105 | University of Texas Southwestern Medical CenterOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT06425926 | Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 117 | Georgiamune IncINDUSTRY | 1 | Aug 14, 2026 | clinicaltrials |
| NCT07622524 | A Phase I Study of CS5007 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 310 | CStone PharmaceuticalsINDUSTRY | 2 | Aug 14, 2026 | clinicaltrials |
| NCT05691517 | Testing How the Body Responds to the Drug CBX-12 in Patients With Advanced Solid Cancers | recruiting | Phase 1 | 35 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2026 | clinicaltrials |
| NCT06167317 | Study of GS-0201 Alone and in Combination in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 278 | Gilead SciencesINDUSTRY | 2 | Aug 13, 2026 | clinicaltrials |
| NCT06384352 | Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 500 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 4 | Aug 13, 2026 | clinicaltrials |
| NCT07266428 | A Study of OTP-01, a Dual Paratopic PD-1/VEGFR2 Antibody, in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 170 | Ottimo Pharma LimitedINDUSTRY | 8 | Aug 13, 2026 | clinicaltrials |
| NCT05272709 | TT-702 in Patients With Advanced Solid Tumours.(CURATE) | recruiting | Phase 1 / Phase 2 | 60 | Cancer Research UKOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05859074 | A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | recruiting | Phase 1 | 56 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT06526819 | SMP-3124LP in Adults With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 120 | Sumitomo Pharma America, Inc.INDUSTRY | 2 | Aug 12, 2026 | clinicaltrials |
| NCT06797336 | A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors | recruiting | Phase 1 | 240 | PAQ Therapeutics, Inc.INDUSTRY | 2 | Aug 12, 2026 | clinicaltrials |
| NCT06840886 | A Study of PHST001 in Advanced Solid Tumors | recruiting | Phase 1 | 272 | Pheast TherapeuticsINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07229612 | A Phase I/II Clinical Study of SHR-4298 Injection in Patients With Malignant Solid Tumors | recruiting | Phase 1 / Phase 2 | 200 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07372625 | A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | recruiting | Phase 1 | 14 | PMV Pharmaceuticals, IncINDUSTRY | 1 | Aug 12, 2026 | clinicaltrials |
| NCT07382544 | Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT05592626 | A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors(START-001) | recruiting | Phase 1 / Phase 2 | 366 | Marengo Therapeutics, Inc.INDUSTRY | 4 | Aug 11, 2026 | clinicaltrials |
| NCT06242470 | A Study of MGC026 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 250 | MacroGenicsINDUSTRY | 3 | Aug 11, 2026 | clinicaltrials |
| NCT07160725 | A Phase 1/2a, First-in-human, Study of BMS-986517 in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 540 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT04855435 | Safety and Preliminary Efficacy of MBS8(1V270) in Cancer Patients With Advanced Solid Tumours | recruiting | Phase 1 | 106 | MonTa Biosciences ApSINDUSTRY | 2 | Aug 10, 2026 | clinicaltrials |
| NCT05111561 | Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer | recruiting | Phase 1 | 42 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06880549 | A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors | recruiting | Phase 1 | 42 | ModernaTX, Inc.INDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07728942 | SLR-108 PET Imaging in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 70 | Solve TherapeuticsINDUSTRY | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05608148 | Clinical Trial of GAIA-102 for Refractory/Relapse Neuroblastomas and Other Malignant Pediatric Solid Tumors | recruiting | Phase 1 | 61 | Kyushu UniversityOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT05944224 | A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 63 | Shanghai Pharmaceuticals Holding Co., LtdINDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 499 | Arvinas Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07751042 | Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab | recruiting | Phase 1 / Phase 2 | 220 | Strand Therapeutics Inc.INDUSTRY | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05176483 | Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors(STELLAR-002) | recruiting | Phase 1 | 1,394 | ExelixisINDUSTRY | 13 | Aug 5, 2026 | clinicaltrials |
| NCT06506643 | Safety and Efficacy of KLS-1 Monotherapy in Malignant Neoplasms | recruiting | Phase 1 / Phase 2 | 36 | Vector Vitale LLCINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT07256756 | A Study of GC203 TIL in Advanced Solid Tumors (NF) | recruiting | Phase 1 | 8 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Aug 5, 2026 | clinicaltrials |
| NCT05238792 | Multi Tumor-Associated Antigen-Specific T Lymphocytes to Treat Patients With High Risk Solid Tumors(ATTACK) | recruiting | Phase 1 | 24 | Children's National Research InstituteOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT06832982 | Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002 | recruiting | Phase 1 | 66 | Shanghai Pushi Medical Science Co. LtdINDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT07744763 | A Phase I/IIa Study of SYS6041 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | Aug 4, 2026 | clinicaltrials |
| NCT05687110 | Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes | recruiting | Phase 1 | 43 | National Cancer Institute (NCI)NIH | 2 | Aug 3, 2026 | clinicaltrials |
| NCT07397338 | Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | recruiting | Phase 1 / Phase 2 | 370 | Revolution Medicines, Inc.INDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07601243 | Study of GS-2426 in Participants With Advanced Solid Tumors | recruiting | Phase 1 | 174 | Gilead SciencesINDUSTRY | 1 | Aug 3, 2026 | clinicaltrials |
| NCT05372640 | Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors | recruiting | Phase 1 | 45 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05691491 | Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness | recruiting | Phase 1 / Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT05039632 | Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies | recruiting | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 30, 2026 | clinicaltrials |
| NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | recruiting | Phase 1 / Phase 2 | 340 | Inhibrx Biosciences, IncINDUSTRY | 4 | Jul 29, 2026 | clinicaltrials |
| NCT07374419 | Atamparib in Patients With Advanced Solid Tumors(PARP7) | recruiting | Phase 1 / Phase 2 | 178 | Nerviano Medical Sciences (Shanghai) Ltd.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07524140 | A First-in-Human Study of ZE94-0605 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 60 | Eilean TherapeuticsINDUSTRY | 2 | Jul 29, 2026 | clinicaltrials |
| NCT05227326 | AOH1996 for the Treatment of Refractory Solid Tumors | recruiting | Phase 1 | 92 | City of Hope Medical CenterOTHER | 1 | Jul 28, 2026 | clinicaltrials |
| NCT05907980 | A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors | recruiting | Phase 1 | 209 | Chugai PharmaceuticalINDUSTRY | 2 | Jul 28, 2026 | clinicaltrials |
| NCT07042100 | A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 | 177 | Sun Pharma Advanced Research Company LimitedINDUSTRY | 3 | Jul 28, 2026 | clinicaltrials |
| NCT04939610 | A Study of 177Lu-FAP-2286 in Advanced Solid Tumors(LuMIERE) | recruiting | Phase 1 / Phase 2 | 222 | Novartis PharmaceuticalsINDUSTRY | 6 | Jul 24, 2026 | clinicaltrials |
| NCT06445517 | Study Evaluating ISM8207 in Participants With Advanced Solid Tumors and Relapsed/Refractory B-Cell Lymphoma | recruiting | Phase 1 | 60 | InSilico Medicine Hong Kong LimitedINDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07002203 | Personalized Neoantigen Peptide Vaccines for Solid Tumors | recruiting | Phase 1 / Phase 2 | 10 | Seqker Biosciences, Inc.INDUSTRY | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07098299 | Metformin Combined With Chemotherapy and/or Immunotherapy in Solid Malignancies | recruiting | Phase 1 | 60 | Barbara Ann Karmanos Cancer InstituteOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07362888 | First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | Adcendo ApSINDUSTRY | 2 | Jul 24, 2026 | clinicaltrials |
| NCT07460375 | A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 191 | LigaChem Biosciences, Inc.INDUSTRY | 3 | Jul 24, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Aug 17, 2026source: clinicaltrials